orphan

(redirected from orphan products)
Also found in: Dictionary, Thesaurus, Medical, Financial, Encyclopedia.
Related to orphan products: Orphan Drug Act

orphan

n. a child, particularly a minor, whose two natural parents are dead. In some cases, such as whether a child is eligible for public financial assistance to an orphan, "orphan" can mean a child who has lost one parent.

orphan

noun abandoned child, abandoned infant, bereaved child, castaway, child without parents, foundling, homeless child, orbus, orphaned child, orphaned infant, parentless child, twice-bereaved child, waif, ward

ORPHAN. A minor or infant who has lost both of his or her parents. Sometimes the term is applied to such a person who has lost only one of his or her parents. 3 Mer. 48; 2 Sim. & Stu. 93; Lo & Man. Inst. B. 1, t. 2, c. 1. See Hazzard's Register of Pennsylvania, vol. 14, pages 188, 1 89, for a correspondence between the Hon. Joseph Hopkinson and ex-president J. Q. Adams as to the meaning of the word Orphan, and Rob. 247.

References in periodicals archive ?
director of FDAs Office of Orphan Product Development, within the Office of Special Medical Programs.
The Rare Diseases Orphan Product Development Act of 2002 increased the funding for FDA's Orphan Products Research Grant Program to $25 million, putting more money toward development of therapies for rare diseases.
Funds for research through Orphan Products Grants Programs benefit from a 50% deduction tax credit for clinical trial expenses (9) and a market exclusivity of 7 years.
They oppose the initiatives by Senators Kennedy and Hatch to amend the law, because companies might be deprived of the fruits of their large investments in orphan product R & D.
Oncology Orphan products Livatag([R]) (Doxorubicin Transdrug[TM]) (primary liver cancer): Phase III on going Validive([R]) (Clonidine Lauriad(TM)) (mucositis): Phase II on going AMEP([R]) (invasive melanoma): Phase I on going
director of the FDAs Office of Orphan Products Development, within the Office of Special Medical Programs.
Cote rejoin the FDA as the new head of the Orphan Products Development office," said Janet Woodcock, M.
1379 will fortify the ORD by making it a permanent office at NIH; giving it statutory authority which will allow it to form its own research agenda; doubling its budget to $4 million in Fiscal Year 2002 and "such sums as may be necessary" for each subsequent fiscal year; authorizing new funds for Rare Disease Research Centers of Excellence in the amount of $20 million; and doubling the funding of the Orphan Product Research Grant Program at the FDA-which receives 100 grant applications yearly-to $25 million in FY 2002.
In the United States currently, 194 drugs and biologics have been brought to market as orphan products, but none are vaccines.
a developer of leading-edge unique therapeutics for the advanced treatment of cancer, has announced that the Office of Orphan Products Development of the FDA has determined that Oncolym qualifies for orphan designation for the treatment of intermediate and high-grade B-Cell Non-Hodgkin's Lymphoma.
Oncology Orphan products Livatag([R]) (Doxorubicin Transdrug[TM]) (primary liver cancer): Phase III on going Validive([R]) (Clonidine Lauriad[TM]) (mucositis): Phase II on going AMEP([R]) (invasive melanoma): Phase I on going
The orphan drug designation is granted by the US FDA Office of Orphan Products Development to drugs being developed for safe and effective treatment of diseases that affect fewer than 200,000 people in the US.